Clinical Experience with Calcitonin Gene-Related Peptide (CGRP) in Patients with Post-Concussion Headaches

Abstract

To evaluate the role of CGRP Antagonists in the management of Post-Concussion Headaches. Headaches are one of the most common, debilitating symptoms experienced in post-concussion patients. Previous studies show these symptoms are mediated through a CGRP dependent mechanism. Injectable monoclonal antibodies directed against CGRP have seen widespread use for the management of migraines since their approval in 2018, however there has been minimal evaluation of their effectiveness in managing post-concussion headaches. A retrospective review of post-concussion patients who were administered intramuscular CGRP Antagonists once monthly in a fixed dose. This study examined reported severity of headaches evaluated at the initial clinical examinations compared to subsequent examinations post-administration of medication. Of 3 subjects evaluated and receiving erenumab (n = 2) or fremanezumab (n = 1), all showed some form of improvement in their symptoms. Mean (SD) age was 51.7 (6.23). Of these subjects, one patient reported = 1 adverse event (AE). No subjects had serious AE that required discontinuation of treatment. CGRP Antagonists show potential to be a useful approach for the management of post-concussion headaches.